Free Trial
NASDAQ:GMTX

Gemini Therapeutics (GMTX) Stock Price, News & Analysis

Gemini Therapeutics logo
$44.29 +0.74 (+1.70%)
As of 05/8/2025

About Gemini Therapeutics Stock (NASDAQ:GMTX)

Key Stats

Today's Range
$43.01
$47.21
50-Day Range
$34.28
$56.92
52-Week Range
$1.16
$14.10
Volume
514,661 shs
Average Volume
189,291 shs
Market Capitalization
$1.92 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Receive GMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gemini Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GMTX Stock News Headlines

Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
See More Headlines

GMTX Stock Analysis - Frequently Asked Questions

Gemini Therapeutics' stock was trading at $63.40 at the beginning of 2025. Since then, GMTX shares have decreased by 30.1% and is now trading at $44.29.
View the best growth stocks for 2025 here
.

Gemini Therapeutics, Inc. (NASDAQ:GMTX) posted its quarterly earnings results on Monday, November, 15th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.04.

Shares of GMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Gemini Therapeutics investors own include Alphabet (GOOG), Meta Platforms (META), NVIDIA (NVDA), Zoom Video Communications (ZM), Activision Blizzard (ATVI), Fiverr International (FVRR) and Shopify (SHOP).

Company Calendar

Last Earnings
11/15/2021
Today
5/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GMTX
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-71,870,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.89 per share
Price / Book
15.33

Miscellaneous

Free Float
37,739,000
Market Cap
$1.92 billion
Optionable
Not Optionable
Beta
-0.12
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:GMTX) was last updated on 5/9/2025 by MarketBeat.com Staff
From Our Partners